Vanadium-Oxide Nanocomposite for Cancer Cell Studies
Official patent title
Method of inhibiting cancer cell viability
Arabic title: طريقة لتثبيط حيوية الخلايا السرطانية
Invention
Invention
Problem
Cancer treatments can be limited by toxicity, poor selectivity, resistance, and inadequate delivery. New candidate materials require careful evidence separating in-vitro cytotoxicity from safety and therapeutic benefit in animals or patients.
Why it matters
Identifying materials that reduce viability in cancer-cell models can create leads for mechanistic, selectivity, toxicology, and drug-development studies, but it is an early preclinical step.
Approach
The method contacts cancer cells with a g-C3N4/V2O5/MgAl2O4 nanocomposite in a 5–15:2–7:75–95 mass relationship at 10–500 µg/mL, with the claim stating at least 85% growth inhibition.
Who may benefit
Potential beneficiaries include oncology researchers, nanomedicine laboratories, pharmaceutical discovery teams, toxicologists, and developers of experimental anticancer materials.
Potential value
The disclosure combines defined ternary composition and physical characterization with reported viability responses in HepG-2 liver-cancer and MCF-7 breast-cancer cell lines.
Background
Background
Conventional chemotherapy may cause systemic toxicity, encounter drug resistance, and distribute poorly to tumors. Nanomaterials are investigated as carriers or active agents because size, composition, and surface properties can alter cellular interactions. A reduction in viability in cultured cancer cells is useful for screening, but it does not by itself establish tumor selectivity, mechanism, exposure, biodistribution, tolerability, or treatment efficacy. The patent evaluates a graphitic-carbon-nitride, vanadium-oxide, and magnesium-aluminate composite as an in-vitro anticancer candidate.
Technology overview
Technology overview
The nanocomposite contains g-C3N4, V2O5, and MgAl2O4, preferably near a 10:5:85 mass relationship. It is described with a 25–75 m²/g BET surface area, 1–10 nm average pore diameter, and 0.01–0.5 cm³/g pore volume. Cultured HepG-2 and MCF-7 cells are contacted with the material; reported IC50 values are 31.86 and 68.51 µg/mL, respectively. XRD and diffraction characterize the composite phases. The evidence is preclinical and in vitro.
Potential applications
Potential applications
- In-vitro oncology research.
- Nanomaterial cytotoxicity screening.
- Mechanism-of-action studies in cancer-cell models.
- Lead generation for preclinical anticancer research.
Evidence-supported advantages
Evidence-supported advantages
- Uses a defined three-component mass relationship.
- Reports responses in two human cancer-cell lines.
- Provides IC50 values for the disclosed tests.
- Includes porosity and crystallographic characterization.
- Avoids implying that in-vitro results are clinical evidence.
Development stage
Development stage
Material characterization and in-vitro cancer-cell viability assays are described; normal-cell selectivity, animal safety, animal efficacy, pharmacology, and clinical testing were not established. The development stage was not independently verified.
Commercial opportunity
Commercial opportunity
The material is an early research lead for oncology or nanotoxicology programs. Advancement requires reproducible assays, normal-cell selectivity, mechanism and uptake studies, genotoxicity and immunotoxicity, pharmacokinetics, formulation and dose-route development, animal efficacy and safety, scalable manufacture, and regulatory review before any therapeutic claim or human use.
Patent classifications
Patent classifications
WIPO IPC
- A61K33/24Preparations for medical, dental or toiletry purposes
- A61K31/53Preparations for medical, dental or toiletry purposes
CPC
- A61P35/00Specific therapeutic activity of chemical compounds or medicinal preparations
- A61K31/53Preparations for medical, dental or toiletry purposes
- A61K33/24Preparations for medical, dental or toiletry purposes
- A61K33/08Preparations for medical, dental or toiletry purposes
Inventors
Inventors
- First inventorMohamed Khairy Abdel Fattah Omran
- InventorBabiker Yagoub Elhadi Abdulkhair
Keywords
Keywords
- cancer cell viability
- HepG-2
- MCF-7
- graphitic carbon nitride
- vanadium pentoxide
- magnesium aluminate
- nanocomposite
- in vitro
Patent document and drawings
Patent document and drawings
The patent publication is mapped to this record. Patent drawings remain within that publication; no separately cleared public media package has been supplied.